emyria

ASX : EMD

For personal use only

Delivering the new paradigm in mental health care

2026 Annual General Meeting Presentation



November 2026

Disclaimer

This presentation has been prepared by Emyria Limited ACN 625 085 734 (Company or Emyria). This presentation is not a financial product or investment advice or recommendation, offer or invitation by any person or to any person to sell or purchase securities in Emyria in any jurisdiction. This presentation contains general information only and does not consider the investment objectives, financial situation and needs of individual investors. Investors should make their own independent assessment of the information in this presentation and obtain their own independent advice from a qualified financial adviser having regard to their personal objectives, financial situation and needs before taking any action. No representation or warranty, express or implied, is made as to the accuracy, completeness, reliability or adequacy of any statements, estimates, opinions or other information, or the reasonableness of any assumption or other statement, contained in this presentation. Nor is any representation or warranty (express or implied) given as to the accuracy, completeness, likelihood of achievement or reasonableness of any forecasts, prospective statements or returns contained in this presentation. Such forecasts, prospective statements or returns are by their nature subject to significant uncertainties and contingencies, many of which are outside the control of Emyria. To the maximum extent permitted by law, Emyria and its related bodies corporate, directors, officers, employees, advisers and agents disclaim all liability and responsibility (including without limitation any liability arising from fault or negligence) for any direct or indirect loss or damage which may arise or be suffered through use or reliance on anything contained in, or omitted from, this presentation. An investment in Emyria securities should be considered speculative and is subject to investment and other known and unknown risks, some of which are beyond the control of Emyria. Emyria does not guarantee any rate of return or the absolute or relative investment performance of Emyria securities. The distribution of this presentation including in jurisdictions outside Australia, may be restricted by law. Any person who receives this presentation must seek advice on and observe any such restrictions.

This release may contain certain forward-looking statements with respect to matters including but not limited to the financial condition, results of operations and business of Emyria and certain of the plans and objectives of Emyria with respect to these items. These forward-looking statements are not historical facts but rather are based on Emyria's current expectations, estimates and projections about the industry in which Emyria operates, and its beliefs and assumptions. Words such as "anticipates," "expects," "intends," "plans," "believes," "seeks," "estimates", "guidance" and similar expressions are intended to identify forward looking statements and should be considered an at-risk statement. Such statements are subject to certain risks and uncertainties, particularly those risks or uncertainties inherent in the process of developing technology and in the endeavour of building a business around such products and services. These statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and other factors, some of which are beyond the control of Emyria, are difficult to predict and could cause actual results to differ materially from those expressed or forecasted in the forward looking statements. Emyria cautions shareholders and prospective shareholders not to place undue reliance on these forward-looking statements, which reflect the view of Emyria only as of the date of this release. The forward-looking statements made in this announcement relate only to events as of the date on which the statements are made. Emyria will not undertake any obligation to release publicly any revisions or updates to these forward-looking statements to reflect events, circumstances or unanticipated events occurring after the date of this announcement except as required by law or by any appropriate regulatory authority.

All medicines carry risks and specialist prescribers, such as registered psychiatrists, are best placed to assess the suitability of a new medication against a patient’s individual circumstances and medical history before proceeding. Adverse effects of MDMA include high blood pressure, increased pulse rate, faintness, and panic attacks, and in some rare cases it can cause loss of consciousness or trigger seizures. Other side effects include involuntary jaw clenching, decreased appetite, restless legs, nausea, headache, sweating and muscle/joint stiffness. Adverse effects of psilocybin can include temporary increase in blood pressure and a raised heart rate. There may be some risk of psychosis in predisposed individuals. The effects of MDMA and psilocybin are unlikely at low doses in the treatment regimens used in psychedelic-assisted psychotherapy while appropriately managed in a controlled environment with direct medical supervision. The risk profile of the MDMA inspired compounds is currently unknown.

The availability of these products is subject to the safety and efficacy of the products being tested through clinical trials. Emyria makes no representations or warranties as to the safety or efficacy of the products or the products’ ability (or the ability of its key compounds) to be used in the treatment of indications such as PTSD. There are currently no approved products containing MDMA, psilocybin or MDMA inspired compounds that the TGA has evaluated for quality, safety and efficacy.

For personal use only

Who are we?

Clinics across four states

5

Treatment beds

18

Patients treated since commencing service

>160

FY26 revenue, up 191%

A$4.05m

For personal use only

emyria

ASX: EMD

Building a National network clinics

Treating PTSD and treatment-resistant depression



1) Patients, clinics, beds and revenue as reported in ASX announcement 8 September 2026

Advanced therapies. Compassionate care.

© Emyria 2024

FY26 revenue up 191% to A$4.05m as the network grew from one clinic to five

Year ended 30 June 2026 vs prior year

For personal use only

Revenue

A$4.05m

FY25: A$1.39m

+191 %

Clinics

5

FY25: 1

+4

Beds

18

FY25: 4

+14

Clinicians trained

~145

FY25: ~30

+383%

Authorised prescribers

17

FY25: 6

+183%

Total patients treated

138

FY25: 24

+475%

- Medibank agreement, national funding
- Government payer access announced (DVA)
- Clinically significant PTSD and TRD results
- Empax Global Partnership Program launched

Australian Government
Department of Veterans' Affairs

* Includes those announced, not yet operational, at 30 June 2026. ** Includes those trained or approved after 30 June 2026. FY26 revenue excludes a ~A$0.2m tax grant (A$4.3m including the grant). FY26 revenue ~US$2.8m.

Significant momentum in psychedelic drug treatments

Recent macro catalysts provide significant tailwinds for Emyria

For personal use only

Big Pharma And Psychedelic Medicine—Eli Lilly's $5.8 Billion Bet

Forbes

Emyria moves on clinical drugs play

BUSINESSNEWS

Trump announces reforms to accelerate access to psychedelic drug treatments

President signed executive order directing FDA to expedite review of psychedelic drugs including ibogaine

AMERICAN PSYCHOLOGICAL ASSOCIATION

FEATURE

The emergence of psychedelics as medicine

A look at the potential of MDMA, ketamine, and psilocybin to help people with treatment-resistant mental health conditions

Compass Pathways Eyes Q4 FDA Filing for Psilocybin Depression Drug After Phase 3 Wins

MarketBeat

Change to classification of psilocybin and MDMA to enable prescribing by authorised psychiatrists

Australian Government

Department of Health, Disability and Ageing

Therapeutic Goods Administration


Emyria is well positioned to leverage this momentum

SOURCES

1. https://psychedelics.berkeley.edu/clinical-trials-map

Potential future treatable conditions

Significant global research in psychedelic drugs



New Treatable Conditions Increase Total Addressable Market

For personal use only

SOURCES
1. https://psychedelics.berkeley.edu/clinical-trials-map

Former US Veteran Affairs Secretary Dr David Shulkin has joined to support US opportunities

Strategic Advisor, appointed September 2026

For personal use only



Dr David Shulkin
Strategic Advisor

As VA Secretary, he led one of the world's largest integrated healthcare systems

350,000+
employees

~1,400
facilities

9m+
US veterans served

Federal healthcare track record

- Under Secretary for Health, appointed by President Obama in 2015
- Secretary of Veterans Affairs under President Trump in 2017, confirmed unanimously by the Senate
- Advisor to 4DMedical (ASX: 4DX) on its US VA strategy since 2023

His role at Emyria

- US federal healthcare and veterans' health opportunities
- Clinical and research partnerships
- Health system, government and industry engagement
- Partnerships with drug developers needing specialist clinical delivery

Source: Emyria ASX announcement, 21 September 2026.

Emyria (ASX:EMD) | Executing strongly

Delivering on commitments to shareholders

For personal use only

Recent Achievements

- 1st Private Health Insurer Funding treatments (Medibank)
- Opened 2nd Perth Empax Clinic
- Opened Brisbane Empax Clinic
- Opened Mornington (Victoria) Clinic
- 12 month PTSD Data Outcomes
- Commenced Empax Global Partnership Program (EGPP)
- Early TRD Data Outcomes announced
- Opened Sydney Clinic
- First DVA approvals

Future Drivers:

- Additional New Sites Confirmed
- 2nd Partner for EGPP
- Clinic utilisation maturing
- New Funders Confirmed
- Leveraging scalable IP to create global partnerships
- New treatable conditions/indications

For personal use only

Contact Information

Greg Hutchinson
ghutchinson@emyria.com

Mary-Ann Rennie
mrennie@emyria.com

Investor / Media Inquiries
investors@emyria.com

emyria

Visit Our Investor Hub